<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895567</url>
  </required_header>
  <id_info>
    <org_study_id>BAC18003</org_study_id>
    <nct_id>NCT03895567</nct_id>
  </id_info>
  <brief_title>Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.</brief_title>
  <acronym>CefREC</acronym>
  <official_title>A Randomised Crossover Study of the Pharmacokinetics, Safety and Tolerability of Two Rectal Formulations of Ceftriaxone Compared to Parenteral Ceftriaxone, in Healthy Thai Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orofino Pharmaceuticals Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, three-way cross-over, randomised, open label comparison of intravenous versus two&#xD;
      rectal dosage forms of ceftriaxone in 37 healthy Thai adults.&#xD;
&#xD;
      The following regimens will be evaluated in random order in all participants:&#xD;
&#xD;
      A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form&#xD;
      test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x&#xD;
      500mg)&#xD;
&#xD;
      Possible schedules: ABC, ACB, BAC, BCA, CAB, CBA. Each recipient will receive a single&#xD;
      treatment dose of each of the three formulations in an order predetermined by a computer&#xD;
      generated randomisation list. This will be a constrained randomisation which ensures&#xD;
      approximately balanced proportions for all six schedules (either 6 or 7 patients per&#xD;
      schedule). There will be a minimum 7 day washout period between doses. The last follow up&#xD;
      visit is 28 (+ 2) days after final dose. Participants lost to follow-up or unevaluable for&#xD;
      any reason before completion of pharmacokinetic sampling after the final dose will be&#xD;
      replaced at the discretion of the investigators with another participant of the same&#xD;
      population, if either sample size or completeness of dataset is compromised.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailablity of rectal formulation</measure>
    <time_frame>Approximately 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of Exposure (AUC0-∞)</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Peak concentration (Cmax)</measure>
    <time_frame>Approximately 100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Absorption rate (Tmax)</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time above a plasma concentration of 1µg/mL (this concentration is above the MIC90 for major neonatal pathogens and is the lower limit of detection of the assay)</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) from the date of the first dose to 28 days after the final dose, according to the MedRA classification.</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of all adverse events from the date of the first dose to 28 days after the final dose, according to the MedRA classification.</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg) A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)</intervention_name>
    <description>Parenteral ceftriaxone&#xD;
Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).</description>
    <arm_group_label>ABC</arm_group_label>
    <arm_group_label>ACB</arm_group_label>
    <arm_group_label>BAC</arm_group_label>
    <arm_group_label>BCA</arm_group_label>
    <arm_group_label>CAB</arm_group_label>
    <arm_group_label>CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)</intervention_name>
    <description>Rectal ceftriaxone formulations&#xD;
Formulation 1 ceftriaxone 500mg + Na-CDC 125mg + dicalcium phosphate (binder)</description>
    <arm_group_label>ABC</arm_group_label>
    <arm_group_label>ACB</arm_group_label>
    <arm_group_label>BAC</arm_group_label>
    <arm_group_label>BCA</arm_group_label>
    <arm_group_label>CAB</arm_group_label>
    <arm_group_label>CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)</intervention_name>
    <description>Rectal ceftriaxone formulations&#xD;
Formulation 2 ceftriaxone 500mg + Na-CDC 125mg + mannitol (binder)</description>
    <arm_group_label>ABC</arm_group_label>
    <arm_group_label>ACB</arm_group_label>
    <arm_group_label>BAC</arm_group_label>
    <arm_group_label>BCA</arm_group_label>
    <arm_group_label>CAB</arm_group_label>
    <arm_group_label>CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or non-pregnant female, aged 18 to 46 years (inclusive)&#xD;
&#xD;
          -  Willing and able to give informed consent to participate in the trial&#xD;
&#xD;
          -  Able, in the investigators opinion, and willing to comply with the study requirements&#xD;
             and followup.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participant who is pregnant, lactating or planning pregnancy during the course&#xD;
             of the study.&#xD;
&#xD;
          -  Presence of any condition which in the judgment of the investigator would affect the&#xD;
             absorption of the rectal formulation e.g. previous surgery, haemorrhoids, inflammatory&#xD;
             bowel disease&#xD;
&#xD;
          -  Irritable bowel syndrome (IBS) or diarrhoea in the 24 hours prior to study drug&#xD;
             administration&#xD;
&#xD;
          -  Presence of any condition which in the judgment of the investigator would place the&#xD;
             participant at undue risk or interfere with the results of the study (e.g. serious&#xD;
             underlying cardiac, renal, hepatic or neurological disease; severe malnutrition;&#xD;
             congenital defects or febrile condition).&#xD;
&#xD;
          -  Seropositive for HIV at screening&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) detected in serum at screening.&#xD;
&#xD;
          -  Seropositive for hepatitis C virus (antibodies to HCV) at screening&#xD;
&#xD;
          -  Participation in a clinical trial and/or has received a drug or a new chemical entity&#xD;
             within 30 days or 5 half-lives, or twice the duration of the biological effect of any&#xD;
             drug (whichever is longer) prior to the first dose of study medication and throughout&#xD;
             the study period.&#xD;
&#xD;
          -  Any medical condition that in the judgment of the investigator would make the&#xD;
             administration of the study treatments unsafe.&#xD;
&#xD;
          -  Use of medications known to have a potentially clinically significant interaction with&#xD;
             ceftriaxone or with sodium chenodeoxycholate (Na-CDC) in the 28 days prior to the&#xD;
             first dose and throughout the study period. This includes aluminium-containing&#xD;
             antacids, colestipol, phenobarbital and the combined oral contraceptive pill.&#xD;
&#xD;
          -  Known 27-hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis)&#xD;
&#xD;
          -  History of anaphylaxis and /or hypotension, laryngeal oedema, wheezing, angioedema or&#xD;
             urticarial rash following treatment with ceftriaxone, another cephalosporin or any&#xD;
             beta lactam (e.g. penicillin).&#xD;
&#xD;
          -  History of any other clinically significant reaction to ceftriaxone, another&#xD;
             cephalosporin or beta lactam e.g. drug induced nephritis, hepatitis, erythema&#xD;
             multiforme that, in the opinion of the investigator, contraindicates participation in&#xD;
             the study.&#xD;
&#xD;
          -  Serious chronic illness.&#xD;
&#xD;
          -  Anaemia (Hb &lt; 10 g/dL)&#xD;
&#xD;
          -  Abnormal baseline laboratory screening tests: ALT, AST, creatinine, platelet count,&#xD;
             total WBC, out of the testing laboratory's normal range&#xD;
&#xD;
          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness.&#xD;
&#xD;
          -  Body Mass Index&gt; 35&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence during the 6 months before study&#xD;
             participation: History of regular alcohol consumption averaging &gt;7 drinks/week for&#xD;
             women or &gt;14 drinks/week for men. One drink is equivalent to 12 g alcohol = 5 oz (150&#xD;
             mL) of wine or 12 oz (360 mL) of beer or 1.5 oz (45 mL) of 80 proof distilled spirits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth A Ashley, MD</last_name>
    <phone>+95(0)1544537</phone>
    <email>liz@tropmedres.ac</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>With participant's consent, participant's clinical data and results from blood analyses stored in our database may be shared with Orofino Pharmaceuticals Group, regulatory authorities, or other researchers to use in the future. However, the other researchers will not be given any information that could identify the participant.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_access_criteria>Requests to share data will be considered by the MORU data access committee in line with the MORU data sharing policy (http://www.tropmedres.ac/data-sharing)</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

